- Home
- NAMS vs PBH Comparison
NAMS vs PBH Comparison
Compare NAMS & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAMS | PBH |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | Netherlands | United States |
| Employees | N/A | 600 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | NAMS | PBH |
|---|---|---|
| Price | $34.68 | $61.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | $45.80 | ★ $86.40 |
| AVG Volume (30 Days) | ★ 1.1M | 439.1K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.04 |
| Revenue | $35,243,000.00 | ★ $1,110,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.50 |
| P/E Ratio | ★ N/A | $15.20 |
| Revenue Growth | ★ 4.91 | N/A |
| 52 Week Low | $14.06 | $57.25 |
| 52 Week High | $42.00 | $90.04 |
Technical Indicators
Market Signals| Indicator | NAMS | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 56.46 |
| Support Level | $34.59 | $59.52 |
| Resistance Level | $37.41 | $62.40 |
| Average True Range (ATR) | 1.79 | 1.44 |
| MACD | -0.40 | 0.32 |
| Stochastic Oscillator | 1.97 | 79.01 |
Price Performance
Historical ComparisonAbout NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About PBH Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.